(Q34754652)

4 August 2017

1 reference

title

Progress toward the development of agents to modulate the cell cycle (English)

1 reference

4 August 2017

Peter L Toogood

1

1 reference

4 August 2017

publication date

1 August 2002

1 reference

Current Opinion in Chemical Biology

4 August 2017

published in

1 reference

4 August 2017

volume

6

1 reference

4 August 2017

issue

4

1 reference

4 August 2017

page(s)

472-478

1 reference

The cell cycle and drug discovery: the promise and the hope

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Small-molecule inhibitors of the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Novel molecules that interact with microtubules and have functional activity similar to Taxol

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Synthesis and antitumor activity of novel C-7 paclitaxel ethers: discovery of BMS-184476.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Preclinical antitumor activity of two novel taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

The epothilones, eleutherobins, and related types of molecules

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

A common pharmacophore for cytotoxic natural products that stabilize microtubules

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Solution structure of (+)-discodermolide

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

The conformations of discodermolide in DMSO.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Novel sulfonate analogues of combretastatin A-4: potent antimitotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Quinazolines as cyclin dependent kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Indenopyrazoles as novel cyclin dependent kinase (CDK) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Crystal structure of human cyclin-dependent kinase 2 in complex with the adenine-derived inhibitor H717

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Structure-based design and protein X-ray analysis of a protein kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

CDK inhibitors: positive and negative regulators of G1-phase progression

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Rescue of Cyclin D1 Deficiency by Knockin Cyclin E

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Cyclin-dependent kinase inhibitors for treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Identification of selective inhibitors of cyclin dependent kinase 4

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6.

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

Mechanisms of cell-cycle checkpoints: at the crossroads of carcinogenesis and drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01

1 reference

https://api.crossref.org/works/10.1016%2FS1367-5931%2802%2900342-3

7 January 2021

10.1016/S1367-5931(02)00342-3

Identifiers

DOI

1 reference

4 August 2017

1 reference